Sinotherapeutics (SH:688247) Zheng Quan Zhi Xing·2025-08-17 16:11Core Viewpoint - The controlling shareholder of Shanghai Xuantai Pharmaceutical Technology Co., Ltd. has voluntarily committed not to reduce its shareholding in the company for the next 24 months, aiming to enhance investor confidence and maintain market stability [1][2]. Shareholder Commitment - The controlling shareholder, Shanghai Lianhe Investment Co., Ltd., has issued a commitment letter stating that from August 25, 2025, to August 24, 2027, it will not reduce its shareholding through various trading methods [1]. - This commitment includes adherence to the non-reduction promise in the event of capital reserve conversion into share capital, stock dividends, or rights issues that generate new shares [1]. Shareholding Status - As of the announcement date, the shareholding status of the controlling shareholder is detailed, although specific numbers and percentages are not provided in the text [1].